G49N Stock Chart & Stats
€0.06
-€0.04(-12.73%)
At close: 4:00 PM EST
€0.06
-€0.04(-12.73%)
Day’s Range― - ―
52-Week Range€0.05 - €0.23
Previous CloseN/A
Volume0.00
Average Volume (3M)166.00
Market Cap
€17.23M
Enterprise Value€29.15M
Total Cash (Recent Filing)€1.67M
Total Debt (Recent Filing)€12.84M
Price to Earnings (P/E)―
Beta-0.97
Next Earnings
Mar 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding246,217,330
10 Day Avg. Volume0
30 Day Avg. Volume166
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)€11.20M
Bulls Say, Bears Say
Bulls Say
Debt ReductionLower debt provides some improvement in financial flexibility and may reduce financing pressure compared with prior years. Although solvency remains constrained by negative equity, deleveraging is a constructive step that could help preserve resources for the company’s development programs.
Improved Cash BurnThe reduction in operating cash outflow indicates that cash consumption moderated year over year, which could extend the company’s funding runway if maintained. This does not remove liquidity risk, but sustained improvement would lessen the pace of external financing needs.
Narrower LossesNarrowing losses suggest some progress in controlling the gap between operating costs and revenue compared with earlier periods. If this trend continues alongside development execution, it could improve the path toward breakeven, despite current profitability remaining deeply negative.
Bears Say
Revenue CollapseThe near-total revenue decline highlights limited commercial scale and makes the business heavily dependent on future pipeline progress rather than established product sales. Such weak top-line support reduces operating leverage and increases the difficulty of funding ongoing development internally.
Negative EquityPersistent negative equity is a material solvency weakness and indicates that the company’s liabilities exceed its recorded asset base. This limits financial flexibility, complicates leverage assessment, and leaves the business more reliant on external capital to continue operating.
Persistent Cash BurnRecurring negative operating cash flow shows that the business is not yet funding its activities through operations. Continued cash consumption can require repeated financing and may constrain investment in the pipeline unless revenue scales or operating outflows decline materially.
GenSight Biologics SA News
G49N FAQ
What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was €0.05 and its highest was €0.23 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €17.23M.
When is GenSight Biologics SA’s upcoming earnings report date?
GenSight Biologics SA’s upcoming earnings report date is Mar 19, 2027 which is in 144 days.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Sep 29, 2026. The company reported -€0.05 earnings per share for the quarter.
Is GenSight Biologics SA overvalued?
According to Wall Street analysts GenSight Biologics SA’s price is currently Overvalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 246,217,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.05 in its last earnings report. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in DE:G49N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GenSight Biologics SA
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.